



Republic of the Philippines
 Department of Health
BAGUIO GENERAL HOSPITAL AND MEDICAL CENTER
 Baguio City

BIDS AND AWARDS COMMITTEE
BID BULLETIN/SUPPLEMENTAL BID

Form No.: MCC-BAC-003
Revision No.: Ø
Effectivity Date: August 1, 2014

Bid Bulletin No.: 2015-04
Date: April 16, 2015

**This Bid Bulletin No. 2015-04 is issued to modify or amend the Bid Documents of VARIOUS DRUGS AND MEDICINES (REBID).
 This shall form integral part of said Bid Documents.**

ORIGINAL	AMENDED
INVITATION TO BID	
1. The Baguio General Hospital & Medical Center (BGHMC) through the Revolving Fund and Hospital Income for the year 2015 intends to apply the sum of <u>Thirty Eight Million Eight Hundred Sixty Three Thousand Two Hundred Fifteen Pesos and Forty-Five Centavos (Php 38,863,215.45)</u> being the Approved Budget for the Contract (ABC)...	1. The Baguio General Hospital & Medical Center (BGHMC) through the Revolving Fund and Hospital Income for the year 2015 intends to apply the sum of <u>Forty Million Two Hundred Thirty Seven Thousand Seven Hundred Fifteen Pesos and Forty Five Centavos (Php 40,237,715.45)</u> being the Approved Budget for the Contract (ABC)...
6. .. Bid opening shall be on April 24, 2015, 10:00 AM. at <u>the BGHMC Dietary Hall.</u> Bids will be opened in the presence of the Bidders' representatives who choose to attend at the address below. Late bids shall not be accepted.	6. .. Bid opening shall be on April 24, 2015, 10:00 AM. <u>at the Under Five Clinic, Conference Room.</u> Bids will be opened in the presence of the Bidders' representatives who choose to attend at the address below. Late bids shall not be accepted.

**SECTION III & SECTION V
(Bid Data Sheet & Special Conditions of the Contract)**

<p>2. The Funding Source is: The Government of the Philippines (GOP) through the Revolving Fund and Hospital Income in the amount of <u>Thirty Eight Million Eight Hundred Sixty Three Thousand Two Hundred Fifteen Pesos and Forty Five Centavos (Php 38,863,215.45).</u></p>	<p>2. The Funding Source is: The Government of the Philippines (GOP) through the Revolving Fund and Hospital Income in the amount of <u>Forty Million Two Hundred Thirty Seven Thousand Seven Hundred Fifteen Pesos and Forty Five Centavos (Php 40,237,715.45).</u></p>
<p>13.2 The ABC is <u>Thirty Eight Million Eight Hundred Sixty Three Thousand Two Hundred Fifteen Pesos and Forty Five Centavos (Php 38,863,215.45).</u></p>	<p>13.2 The ABC is <u>Forty Million Two Hundred Thirty Seven Thousand Seven Hundred Fifteen Pesos and Forty Five Centavos (Php 40,237,715.45).</u></p>
<p>SECTION III: 12.1 (A)(i) Additional Requirements: (To be submitted during post qualification whenever required): ...</p>	<p>SECTION III: 12.1 (A)(i) Additional Requirements: (To be submitted during post qualification whenever required): ... 7. REQUIREMENTS for INTRAVENOUS ANTIBIOTICS: 1) Innovator drugs – no need for Certificate of Analysis, studies 2) Generic IV drugs: a. Original or authenticated Certificate of Analysis of the latest batch of products (Lot number of tested antibiotic should be the same as stocks to be delivered). Certificate of Analysis should indicate the purity of the antibiotic. Certificate of analysis should be done locally preferably at UP or UST OR b. Certificate/Notice of Award if currently a winning bidder at UP-PGH (because certificates of analysis are required for bidding in UP-PGH) OR</p>
	<p>c. Randomized controlled trials in which the drug used is the BRAND of drug of the bidder d. Should submit a complete list of the components/ingredients of the drug including excipients (to be included in the specs).</p>

	<p>REQUIREMENTS for ORAL DRUGS (Reference FDA Circular 2013-014)</p> <p>Products requiring Bioequivalence Studies in addition to Rifampicin, Atenolol, Metoprolol, Propranolol, Nicardipine, Nifedipine, Diltiazem, Gluciclazide, Metformin, Phenytoin, PZA and Theophylline (BC No. 2006-0008)</p> <ol style="list-style-type: none"> 1) CLASS 4 Drugs 2) CLASS 2 3) Subsequent generic products to be marketed after patent expiration of innovator 4) All modified release pharma products
	<p>CLASS 4 DRUGS (based on WHO)</p> <ol style="list-style-type: none"> 1) Drugs on WHO-EML <ol style="list-style-type: none"> a) Acetazolamide b) Furosemide c) Glibenclamide d) Haloperidol e) Retinol palmitate f) Spironolactone g) Sulfasalazine h) Albendazole i) Artemether + Lumefantrine j) Azithromycin k) Cefixime l) Clofazimine m) Diloxanidefuroate n) Efavirenz o) Erthromycin p) Inidnavir Sulfate q) Ivermectin
	<ol style="list-style-type: none"> r) Mebendazole s) Lopinavir + Ritonavir t) MefloquineHcl u) Nelfinavirmesilate v) Niclosamide w) Pyrantelpamoate x) Pyrimethamine

	<p>2) Complimentary List in WHO - EML</p> <ul style="list-style-type: none">a) Azathioprine Nab) Artesunatec) Cyclosporind) Etoposidee) Mercaptopurinef) Mifepristoneg) Oxamniquineh) P-aminosalicylic acidi) Sulfadiazinej) Pyrimethamine in Sulfadoxine + Pyrimethamine
	<p>CLASS 2 (Not eligible for biowaiver)</p> <ul style="list-style-type: none">a) Carbamazepineb) Dapsonec) Griseofulvind) Iopanoic Acide) Nevirapinef) Nitrofurantoing) Praziquantelh) Sulfamethoxazole + Trimethoprimi) Trimethoprimj) Verapamil Hclk) Ibuprofenl) Phenytoin Na

	<p>For Biowaiver (Class 1, 2 and 3) or Bioequivalence: Biowaiver– An applicant should be able to produce documented evidence (either through peer-reviewed scientific literature or in its absence, actual laboratory testing) that a product may avail of biowaiver based on the solubility and permeability of its API, and the dissolution characteristic of the dosage form. Otherwise, a satisfactory BE study report is required.</p> <p>CLASS 1 a) ASA b) Allopurinol c) Amiloride d) AmitryptilineHcl e) Amlodipine f) Amoxicillin</p>
	<p>g) Ascorbic Acid h) Chloroquine PO4 or SO4 i) Diazepam j) Digoxin k) Doxycycline Hcl l) Fluconazole m) Lamivudine n) Levonorgestrel o) Lithium carbonate p) DL-Methionine q) Metronidazole r) Nicotinamide s) Norethisterone t) Paracetamol u) Phenobarbital v) Phenoxyethyl potassium w) Potassium iodide x) Prednisolone y) Primaquine di PO4 z) ProguanilHcl</p>

	<ul style="list-style-type: none"> aa) Promethazine Hcl bb) PropanololHcl cc) PTU dd) Pyridoxine Hcl ee) Quinine SO4 and bi SO4 ff) Riboflavin gg) Salbutamol SO4 hh) Stavudine ii) Valproic Acid Na jj) Warfarin Na kk) Zidovudine
	<p>Complimentary list</p> <ul style="list-style-type: none"> a) Cafolinate b) Clindamycin c) Cyclophosphamide d) Diethylcarbamazinedihydrogen citrate e) Levofloxacin f) Ofloxacin g) Prednisone h) Tamoxifen citrate
	<p>CLASS 3</p> <ul style="list-style-type: none"> a) Abacavir b) Acyclovir c) Amiodaquine d) Atenolol e) Clavulanic Acid in Amoxicillin + Clavulanic Acid f) Benznidazole g) BiperidenHcl h) Chloramphenicol i) Chlorpheniramine hydrogen maleate j) Chlorpromazine Hcl k) Cloxacillin Na l) Codeine PO4 m) Didanosine n) Enalapril o) Ergocalciferol

	<p>p) EthambutolHcl q) Ethinyl estradiol r) Ethinyl estradiol in Ethinyl estradiol + Levonogestrel s) Ethinyl estradiol in Ethinyl estradiol + Norethisterone t) Ferrous So4 u) Ferrous SO4 + FA v) Folic Acid w) Glyceryltrinitrate (Sublingual) x) Hydralazine HCl y) HCTZ z) INH</p>
	<p>aa) INH + ETH bb) ISDN cc) Levamisole HCL dd) Carbidopa in Levodopa + Carbidopa ee) Levothyroxine Sodium ff) Metformin HCl gg) Methyl dopa hh) Metoclopramide HCl ii) Morphine So4 jj) Neostigmine bromide kk) Nifurtimox ll) Penicillamine mm) PZA</p>
	<p>nn) Ranitidine HCl oo) INH in RIF + INH pp) INH in RIF + INH + PZA qq) INH in RIF + INH + PZA + ETH</p>
7. Other appropriate Licenses required by law	8. Other appropriate Licenses required by law
<p>24.1 The place of bid opening is at the <u>Dietary Hall</u>, Baguio General Hospital & Medical Center, Baguio City. The date and time of bid opening is April 24, 2015 @ 10:00 A.M.</p>	<p>24.1 The place of bid opening is at the <u>Under Five Clinic, Conference Room</u>, Baguio General Hospital & Medical Center, Baguio City. The date and time of bid opening is April 24, 2015 @ 10:00 A.M.</p>

<p>33.1 Performance Security shall be in the form of Cash or Cashier's Manager's Check only issued by a Universal or Commercial Bank equal to five percent (5%) of the Total Contract Price.</p>	<p>33.1 Performance Security shall be in the form of:</p> <p>1. Cash or Cashier's/Manager's Check issued by by a Universal or Commercial Bank equal to five percent (5%) of the Total Contract Price;</p> <p><u>OR</u></p> <p>2. Bank draft/guarantee or irrevocable letter of credit issued by a Universal or Commercial Bank: Provided, however, that it shall be confirmed or authenticated by a Universal or Commercial Bank, if issued by a foreign bank equal to five percent (5%) of the Total Contract Price.</p>
<p>SECTION V: pages 8 to 12 Requirements for Intravenous Antibiotics..</p>	<p>(deleted) Transferred to Section III: 12.1(A) (i): Additional Requirements (To be submitted during post qualification whenever required):</p>
<p>SECTION VII: TECHNICAL SPECIFICATIONS</p>	
<p>Item No. 58: D5 LRS, 500ml, plastic bottle Unit Cost: <u>Php 15.13</u> Total Cost: <u>Php 60,500.00</u></p>	<p>Item No. 58: D5 LRS, 500ml, plastic bottle Unit Cost: <u>Php 20.00</u> Total Cost: <u>Php 80,000.00</u></p>
<p>Item No. 101: Isoflurane, 100ml bottle Unit Cost: <u>Php 645.00</u> Total Cost: <u>Php 645,000.00</u></p>	<p>Item No. 101: Isoflurane, 100ml bottle Unit Cost: <u>Php 2,000.00</u> Total Cost: <u>Php 2,000,000.00</u></p>

	<p>Please see attached the correct numbering and sequence of the items to be bid under Section VII: Technical Specifications Note: This shall be used as the final basis for the Bidder's Compliance under Eligibility Requirements.</p>
--	--

BIDS AND AWARDS COMMITTEE

(ON LEAVE)

RAY P. SUANDING, MD

Chairman

(SGD.)

EDWARD C. PUDLAO, CPA, MBA

Vice Chairman

(SGD.)

ATTY. PATRICK HENRY M. VILLANUEVA

Member

(SGD.)

KERIMA DIVITA O. MANANTAN, MD

Member

(SGD.)

RAINELDA T. AREOLA

Member

Approved by:

(SGD.)

EMMANUEL F. ACLUBA, MD, MHA

Medical Center Chief II